AstraZeneca and Oxford University are set to sideline the "lucky mistake" data which boosted the Phase III results of their COVID-19 vaccine earlier this week, after facing criticism about how the study was performed and doubts about the robustness of the interim data.
The partners are now emphasizing the lower 62% efficacy level from their trials in patients who received both high doses...







